Enhancement of vaccine potency through improved delivery.
The need for more potent, safe and well-characterised vaccines has necessitated the discovery and development of new vaccine technologies. These include adjuvants to target the innate immune system to provide a stimulus that potentiates the development of an antigen-specific immune response, and delivery systems to ensure that the antigen and adjuvant are localised to the appropriate immune compartments. Several such technologies are being tested in human clinical trials and a few have been licensed for limited use in human vaccines. This review will highlight some of the promising technologies that may have an impact on how vaccines are administered.
Chiron Corporation, 4560 Horton St, mailstop 4.3, Emeryville, CA 94608, USA. jeffrey_ulmer@chiron.com
Jeffrey B
JB
Ulmer
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000818:Animals; D000917:Antibody Formation; D002648:Child; D002986:Clinical Trials as Topic; D004333:Drug Administration Routes; D006801:Humans; D016882:ISCOMs / Q000276:immunology; D007113:Immunity, Innate; D051379:Mice; D018448:Models, Immunological; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D016882:ISCOMs; D014612:Vaccines; D022223:Vaccines, Subunit